Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression

Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression

Background: Serum brain-derived neurotrophic factor (BDNF) is decreased in individuals with major depressive disorder (MDD). Pre-clinical and clinical reports suggest that the glutamate release inhibitor riluzole increases BDNF and may have antidepressant properties. Here we report serum (sBDNF) and...

Full description

Bibliographic Details
Main Authors: Banasr, M. (Author), Haile, C. (Author), Kiselycznyk, C. (Author), Mathew, S.J (Author), Webler, R.D (Author), Wilkinson, S.T (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2018
Subjects:
adolescent
Adolescent
adult
Adult
aged
Aged
amino acid receptor blocking agent
antidepressant agent
Antidepressive Agents
Article
BDNF
blood
brain derived neurotrophic factor
Brain-Derived Neurotrophic Factor
clinical outcome
comparative study
controlled study
Depressive Disorder, Major
Depressive Disorder, Treatment-Resistant
disease severity
DSM-IV
Excitatory Amino Acid Antagonists
female
Female
human
Humans
lack of drug effect
major clinical study
major depression
male
Male
MDD
middle aged
Middle Aged
Montgomery Asberg Depression Rating Scale
parallel design
pathophysiology
placebo
plasma
Plasma
priority journal
prospective study
protein blood level
randomized controlled trial
riluzole
Riluzole
serum
Serum
treatment resistant depression
young adult
Young Adult
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items